Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHASE 1 SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066, A MET/HGFR SELECTIVE TYROSINE KINASE INHIBITOR, ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER

Next Previous
Trial Profile

PHASE 1 SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066, A MET/HGFR SELECTIVE TYROSINE KINASE INHIBITOR, ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crizotinib (Primary) ; Itraconazole; Rifampicin
  • Indications Adenocarcinoma; Anaplastic large cell lymphoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Acronyms PROFILE-1001
  • Sponsors Pfizer

Most Recent Events

  • 11 May 2022 Results assessing patient-level data from the VISION study and comparison with GEOMETRY mono-1 (capmatinib), NCT02897479 (savolitinib) and PROFILE 1001 (crizotinib) studies in patients with advanced NSCLC published in the Advances in Therapy
  • 15 Feb 2022 Status changed from active, no longer recruiting to completed.
  • 03 Mar 2021 Results (n=38) of sub analysis assessing MET-amplified NSCLC patients response to crizotinib, published in the Journal of Thoracic Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top